This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Poniard Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript

Poniard Pharmaceuticals, Inc. (PARD)

Q1 2010 Earnings Call

May 10, 2010 4:30 pm ET


Ronald Martell - CEO

Dr. Michael Perry - President & CMO

Greg Weaver - CFO

Susan Neath - Investor Relations


Simos Simeonidis - Rodman & Renshaw



Good day and welcome to the Poniard Pharmaceuticals first quarter 2010 earnings conference call. Today's conference is being recorded. At this time, I’d like to turn the conference over to Susan Neath. Please go ahead Susan.

Susan Neath

Good afternoon, and thank you for joining us to discuss the results of Poniard Pharmaceuticals first quarter 2010 earnings conference call. Poniard issued a press release this afternoon that is available on the company’s website at

Comments made on this call will contain forward-looking statements relating to the company’s picoplatin and product candidate and describing the company’s corporate strategies and objectives, regulatory and partnering efforts, product development activities, clinical and regulatory goals, financial conditions, future expectations, prospectus, projections and believes.

Actual results and events may differ materially from those indicated in these forward-looking statements based on a number of important factors including risks and uncertainties inherent in the company’s business including the company’s anticipated future operating losses, future capital requirement and ability to obtain future funding.

Direct strategic partners relationships may not be established on a timely basis on terms that are ultimately favorable to the company or at all the potential safety efficacy and commercial viability of the company picoplatin product candidates, the risk that the company’s additional analysis of data some clinical trails of picoplatin may produce negative or inconclusive results are maybe inconsistent with previously announced results are previously conducted trials.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
PARD $0.14 75.00%
AAPL $109.91 -0.79%
FB $93.29 -0.77%
GOOG $644.40 0.46%
TSLA $237.46 -3.50%


Chart of I:DJI
DOW 16,795.74 +19.31 0.12%
S&P 500 1,980.34 -6.71 -0.34%
NASDAQ 4,747.1770 -34.0870 -0.71%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs